Article Text

other Versions

PDF
Cohort study
Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD
  1. Patrick White
  1. Department of Primary Care & Public Health Sciences, Kings College London, London, UK
  1. Correspondence to: Dr Patrick White, Primary Care & Public Health Sciences, Kings College London, 9th Floor Capital House, 42 Weston Street, London SE1 3QD, UK; patrick.white{at}kcl.ac.uk

Statistics from Altmetric.com

Commentary on: OpenUrlAbstract/FREE Full Text

Context

High-dose inhaled corticosteroids (ICS) reduce the rate of exacerbations in severe and very severe chronic obstructive pulmonary disease (COPD) when prescribed with inhaled long-acting β-agonists (LABA).1 ,2 Although LABA+ICS use is now universally recommended for severe and very severe COPD, the magnitude of their effect is disputed and they are associated with a higher risk of pneumonia.3 Risk of pneumonia has been associated particularly with fluticasone propionate, and less clearly with budesonide.4 ,5 Equivalence of potency between …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.